Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center